PL2082225T3 - Sposób określania czy komórka nowotworowa ma potencjał inwazyjny i/lub metastatyczny oraz środki modulujące złośliwą transformację - Google Patents
Sposób określania czy komórka nowotworowa ma potencjał inwazyjny i/lub metastatyczny oraz środki modulujące złośliwą transformacjęInfo
- Publication number
- PL2082225T3 PL2082225T3 PL07823920T PL07823920T PL2082225T3 PL 2082225 T3 PL2082225 T3 PL 2082225T3 PL 07823920 T PL07823920 T PL 07823920T PL 07823920 T PL07823920 T PL 07823920T PL 2082225 T3 PL2082225 T3 PL 2082225T3
- Authority
- PL
- Poland
- Prior art keywords
- invasive
- determine whether
- tumour cell
- modulating agents
- metastatic potential
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0618486.5A GB0618486D0 (en) | 2006-09-20 | 2006-09-20 | Assay |
GB0625379A GB0625379D0 (en) | 2006-12-20 | 2006-12-20 | Assay |
PCT/GB2007/003599 WO2008035096A1 (en) | 2006-09-20 | 2007-09-20 | Assay |
EP07823920.9A EP2082225B1 (en) | 2006-09-20 | 2007-09-20 | Method to determine whether a tumour cell has invasive and/or metastatic potential and modulating agents of malignant transformation |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2082225T3 true PL2082225T3 (pl) | 2014-06-30 |
Family
ID=38988374
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL07823920T PL2082225T3 (pl) | 2006-09-20 | 2007-09-20 | Sposób określania czy komórka nowotworowa ma potencjał inwazyjny i/lub metastatyczny oraz środki modulujące złośliwą transformację |
Country Status (7)
Country | Link |
---|---|
US (1) | US8609332B2 (pl) |
EP (1) | EP2082225B1 (pl) |
DK (1) | DK2082225T3 (pl) |
ES (1) | ES2453374T3 (pl) |
PL (1) | PL2082225T3 (pl) |
PT (1) | PT2082225E (pl) |
WO (1) | WO2008035096A1 (pl) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2970884A4 (en) | 2013-03-14 | 2016-11-02 | Univ Florida | PROTEINS CONTAINING DIAMINATE CARBOXYLIC ACID REPETITIONS ASSOCIATED WITH ALS |
US10940161B2 (en) | 2016-04-04 | 2021-03-09 | University Of Florida Research Foundation, Incorporated | Manipulation of EIF3 to modulate repeat associated non-ATG (RAN) translation |
CA3060250A1 (en) | 2017-04-17 | 2018-10-25 | University Of Florida Research Foundation, Incorporated | Regulation of ran protein translation by pkr and eif2a-p pathways |
EP3688020A4 (en) * | 2017-09-25 | 2021-07-14 | University of Florida Research Foundation, Incorporated | IMMUNOLOGICAL DOSAGE FOR THE DETECTION OF RAN PROTEINS |
US11903910B2 (en) | 2017-09-26 | 2024-02-20 | University Of Florida Research Foundation, Incorporated | Use of metformin and analogs thereof to reduce RAN protein levels in the treatment of neurological disorders |
GB201915598D0 (en) * | 2019-10-28 | 2019-12-11 | Univ Bradford | Methods for determining the invasive and/or metastic potential of a tumour |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6613534B2 (en) * | 2001-03-20 | 2003-09-02 | Wake Forest University Health Sciences | MAP-2 as a determinant of metastatic potential |
AU2003294828A1 (en) * | 2002-12-17 | 2004-07-09 | Sinogenomax Co. Ltd. Chinese National Human Genomecenter | Specific markers for pancreatic cancer |
WO2005032495A2 (en) | 2003-10-03 | 2005-04-14 | Bayer Pharmaceuticals Corporation | Gene expression profiles and methods of use |
US7521195B1 (en) * | 2005-07-21 | 2009-04-21 | Celera Corporation | Lung disease targets and uses thereof |
-
2007
- 2007-09-20 WO PCT/GB2007/003599 patent/WO2008035096A1/en active Application Filing
- 2007-09-20 DK DK07823920.9T patent/DK2082225T3/da active
- 2007-09-20 ES ES07823920.9T patent/ES2453374T3/es active Active
- 2007-09-20 PT PT78239209T patent/PT2082225E/pt unknown
- 2007-09-20 PL PL07823920T patent/PL2082225T3/pl unknown
- 2007-09-20 EP EP07823920.9A patent/EP2082225B1/en not_active Not-in-force
- 2007-09-20 US US12/311,192 patent/US8609332B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP2082225B1 (en) | 2014-01-01 |
EP2082225A1 (en) | 2009-07-29 |
DK2082225T3 (da) | 2014-04-07 |
US20090312395A1 (en) | 2009-12-17 |
PT2082225E (pt) | 2014-04-10 |
US8609332B2 (en) | 2013-12-17 |
ES2453374T3 (es) | 2014-04-07 |
WO2008035096A1 (en) | 2008-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1993553A4 (en) | METHODS FOR THE TREATMENT OF CANCER AND THE MODULATION OF STEM CELLS | |
EP2274617A4 (en) | METHODS FOR IDENTIFYING AND USING AGENTS TARGETING CANCER STEM CELLS | |
GB201005548D0 (en) | Neural tumor stem cells and methods of use thereof | |
EP2099375A4 (en) | METHODS AND DEVICES FOR MINIMAL INVASION FOR THE TREATMENT OF PROSTATE DISEASES | |
PL2082225T3 (pl) | Sposób określania czy komórka nowotworowa ma potencjał inwazyjny i/lub metastatyczny oraz środki modulujące złośliwą transformację | |
HK1149032A1 (en) | Methods and agents for improving targeting of cd138 expressing tumor cells cd138 | |
EP2232670A4 (en) | INTELLIGENT BATTERY SYSTEM AND METHODS OF USE | |
AP2010005186A0 (en) | Method for the production of humus-and nutrient -rich and water-storing soils or soil substrates forsustainable land use and development systems | |
EP1999658A4 (en) | CREATION AND USE OF RELATIONAL TAGS | |
EP2134855A4 (en) | PROGNOSIS, DIAGNOSIS AND USES IN THE TREATMENT OF FANCI CANCER AND FANCI MODULATION AGENTS | |
EP2000543A4 (en) | METHOD FOR THE MOLECULAR DIAGNOSIS OF PROSTATIC CANCER AND NECESSARY FOR CARRYING OUT SAID METHOD | |
EP2142673A4 (en) | NUCLEIC ACID GENES AND COMPLEXES AND METHOD OF USE THEREOF | |
IL214409A (en) | Micro-nutrient fertilizers and methods for their production and use | |
EP2028492A4 (en) | TUMOR MARKERS AND METHOD FOR DETERMINING THE IMPACT OF ANY CANNULAR DISEASE | |
GB0823091D0 (en) | Exfoliating vermiculite and other minerals | |
GB2443436B (en) | Method of determing properties of the earth using turning wave data | |
EP2001462A4 (en) | INHIBITION OF MICROTUBULAR PROTRUSION IN CANCER CELLS | |
EP2164978A4 (en) | COMPOSITIONS AND METHODS FOR MODULATING ADAMTS13 ACTIVITY | |
EP2052089A4 (en) | EMBRYONIC STEM CELL MARKERS FOR CANCER DIAGNOSIS AND PROGNOSIS | |
EP1989216A4 (en) | DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | |
EP2445529A4 (en) | IN CANCER STEM CELLS DIFFERENTLY EXPRESSED MARKERS AND METHOD OF USE THEREOF | |
IL201254A0 (en) | 5 - oxo - isoxazoles as inhibitors of lipases and phospholipases | |
IL200767A0 (en) | Methods for detecting and modulating the sensitivity of tumour cells to anti-mitotic agents | |
GB2460009B (en) | Compounds and methods for the modulation of beta-1 integrin function to mediatetissue repair | |
IL206990A0 (en) | Detection of gstp1 hypermethylation in prostate cancer |